Revelation Biosciences (REVB) Change in Account Payables (2021 - 2025)
Revelation Biosciences (REVB) posted quarterly Change in Account Payables of -$442450.0 for Q4 2025, up 81.12% year-over-year from -$244282.9 in Q4 2024, and down 331.58% quarter-over-quarter from $191057.0 in Q3 2025.
Revelation Biosciences (REVB) Change in Account Payables (2021 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Change in Account Payables for 5 consecutive years, with -$442450.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Account Payables rose 81.12% year-over-year to -$442450.0; the TTM figure through Dec 2025 stood at -$206120.0 (up 64.23% YoY), while the FY2025 annual figure was -$206120.0, up 64.23% from the prior year.
- Change in Account Payables declined to -$442450.0 in Q4 2025 per REVB's latest filing, from $191057.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.8 million in Q3 2024 and bottomed at -$2.3 million in Q4 2024.
- Historically, Change in Account Payables has averaged -$48421.0 across 5 years, with a median of $97129.0 in 2021.
- On a YoY basis, Change in Account Payables climbed as much as 437.64% in 2024 and fell as far as 8259.47% in 2024.
- Revelation Biosciences' Change in Account Payables stood at -$434840.0 in 2021, then soared by 116.14% to $70204.0 in 2022, then slumped by 59.08% to $28724.0 in 2023, then plunged by 8259.47% to -$2.3 million in 2024, then jumped by 81.12% to -$442450.0 in 2025.
- Business Quant data shows REVB's Change in Account Payables at -$442450.0 in Q4 2025, $191057.0 in Q3 2025, and $203836.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -442,450.00 |
| Dec 31, 2025 | -442,450.00 |
| Sep 30, 2025 | 191,057.00 |
| Sep 30, 2025 | 191,057.00 |
| Jun 30, 2025 | 203,836.00 |
| Jun 30, 2025 | 203,836.00 |
| Mar 31, 2025 | -158,563.00 |
| Mar 31, 2025 | -158,563.00 |
| Dec 31, 2024 | -2.34 Mn |
| Dec 31, 2024 | -2.34 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Jun 30, 2024 | -400,342.00 |
| Jun 30, 2024 | -400,342.00 |
| Mar 31, 2024 | 321,767.00 |
| Mar 31, 2024 | 321,767.00 |
| Dec 31, 2023 | 28,724.00 |
| Dec 31, 2023 | 28,724.00 |
| Sep 30, 2023 | 343,358.00 |
| Sep 30, 2023 | 343,358.00 |